Rhythm Pharmaceuticals, Inc. (RYTM) stock
RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30249% above fair value
$109.86−2.30 (-2.05%)
Close on Nov 12, 2026Market cap $7.56BP/E –Yield –
Rhythm Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Rhythm Pharmaceuticals's ebitda for the twelve months ending Dec 31, 2021 was -$169.24M. For fiscal 2025 it was -$191.52M. The highest annual figure on record is -$25.76M in fiscal 2016.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$191.52M | – |
| FY2024 | Dec 31, 2024 | -$264.80M | – |
| FY2023 | Dec 31, 2023 | -$183.46M | – |
| FY2022 | Dec 31, 2022 | -$178.26M | – |
| FY2021 | Dec 31, 2021 | -$169.24M | – |
| FY2020 | Dec 31, 2020 | -$135.89M | – |
| FY2019 | Dec 31, 2019 | -$145.17M | – |
| FY2018 | Dec 31, 2018 | -$77.98M | – |
| FY2017 | Dec 31, 2017 | -$32.19M | – |
| FY2016 | Dec 31, 2016 | -$25.76M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | -$51.01M | – |
| Q3 FY2021 | Sep 30, 2021 | -$43.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$40.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$34.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$34.90M | – |
| Q3 FY2020 | Sep 30, 2020 | -$34.11M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.75M | – |
| Q1 FY2020 | Mar 31, 2020 | -$35.13M | – |
| Q4 FY2019 | Dec 31, 2019 | -$34.03M | – |
| Q3 FY2019 | Sep 30, 2019 | -$36.92M | – |
| Q2 FY2019 | Jun 30, 2019 | -$43.94M | – |
| Q1 FY2019 | Mar 31, 2019 | -$30.28M | – |
| Q4 FY2018 | Dec 31, 2018 | -$26.94M | – |
| Q3 FY2018 | Sep 30, 2018 | -$19.14M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.96M | – |
| Q1 FY2018 | Mar 31, 2018 | -$16.94M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.92M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.23M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.70M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.34M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.32M | – |
See a number that looks wrong?